| gemcitabine / Generic mfg. |
NCT00006010: Gemcitabine Plus Docetaxel in Treating Patients With Unresectable or Metastatic Liver Cancer |
|
|
| Completed | 2 | 25 | US, Canada | docetaxel, gemcitabine hydrochloride | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Liver Cancer | 05/04 | 04/08 | | |
NCT00009893: Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer |
|
|
| Completed | 2 | 42 | US | fluorouracil, gemcitabine hydrochloride, leucovorin calcium | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer | 01/05 | 10/09 | | |
SAKK 44/02, NCT00073905: Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer |
|
|
| Completed | 2 | 44 | Europe | capecitabine plus gemcitabine | Swiss Group for Clinical Cancer Research | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pain | 06/06 | 01/09 | | |
NCT00250822: Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter |
|
|
| Completed | 2 | 11 | US | Gemcitabine and Oxaliplatin | New Mexico Cancer Care Alliance | Liver Cancer | 07/06 | 07/06 | | |
NCT00142467: Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma |
|
|
| Completed | 2 | 33 | US | Gemcitabine, Gemzar, Oxaliplatin, Eloxatin, Bevacizumab, Avastin | Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Genentech, Inc., Sanofi-Synthelabo, Eli Lilly and Company | Hepatocellular Carcinoma | 08/06 | 06/11 | | |
NCT00703365: Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Completed | 2 | 45 | RoW | Sorafenib and Gemcitabine, Nexavar and Gemzar | Mahidol University, Bayer, Chulalongkorn University, Bumrungrad International Hospital | Carcinoma, Hepatocellular | 01/10 | 08/11 | | |
|
NCT01151761: Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation |
|
|
| Terminated | 2 | 2 | US | Stereotactic Body Radiotherapy, External photon radiation, Gemcitabine, Gemzar, Cisplatin, Platinol, Platinol-AQ, Carboplatin, Paraplatin, Paraplatin-AQ, Capecitabine, Xeloda, 5FU, Fluorouracil, Adrucil, Carac, Efudix, Efudex, Fluoroplex, Liver transplantation | Stanford University | Cholangiocarcinoma, Hepatobiliary Neoplasm, Liver Cancer, Bile Duct Cancer, Cancer of Gallbladder | 04/12 | 07/12 | | |
| Completed | 2 | 174 | Europe | ZD6474, Vandetanib, Zactima, Gemcitabine, Gemzar, Placebo matching ZD6474 | Genzyme, a Sanofi Company | Biliary Tract Cancer, Gallbladder Cancer, Cancer Of The Extrahepatic Bile Duct, Ampullary Carcinoma | 09/12 | 09/12 | | |
NCT00832637: Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers |
|
|
| Terminated | 2 | 33 | US | Cisplatin, Platinol®, Erlotinib, Tarceva®, Gemcitabine, Gemzar® | New Mexico Cancer Care Alliance | Hepatocellular Carcinoma, Cholangiocellular Carcinoma, Cholangiocarcinoma of the Extrahepatic Bile Duct, Bile Duct Cancer, Periampullary Adenocarcinoma, Gallbladder Cancer, Extrahepatic Bile Duct Cancer | 06/13 | 03/17 | | |
NCT00808145: Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) |
|
|
| Withdrawn | 2 | 0 | US | Gemcitabine / Cisplatin / Sorafenib, nexavar - sorafenib, gemzar - gemcitabine, cisplatin | Lahey Clinic | Hepatocellular Carcinoma | 10/14 | 10/14 | | |
NCT01581307: Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets |
|
|
| Completed | 2 | 9 | US | FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin), Leucovorin, LV, FOL, OX, 5-Fluorouracil (5-FU), FOLFOX, ELOXATIN, TheraSpheres, radiotherapy, radioembolization | H. Lee Moffitt Cancer Center and Research Institute, BTG International Inc. | Liver Cancer, Pancreatic Cancer | 02/16 | 03/16 | | |
NCT02254681: Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC |
|
|
| Terminated | 2 | 6 | US | Gemcitabine, Gemzar, Cisplatin, Platinol, low dose radiotherapy | Allina Health System | Intrahepatic Cholangiocarcinoma | 09/16 | 09/16 | | |
MispheC, NCT01912053: Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma |
|
|
| Completed | 2 | 41 | Europe | Therasphere® in association with Gemcitabine and Cisplatin, 90-Yttrium theraspheres | Center Eugene Marquis | Cholangiocarcinoma | 12/16 | 11/17 | | |
NCT00059865: Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer |
|
|
| Completed | 1/2 | 68 | US | gemcitabine hydrochloride, pemetrexed disodium | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer | 02/07 | 02/08 | | |
NCT00645710: Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery |
|
|
| Completed | 1/2 | 16 | US | gemcitabine hydrochloride, dFdC, dFdCyd, difluorodeoxycytidine hydrochloride, gemcitabine, Gemzar, LY-188011, floxuridine, 5-FUDR, FdUrD, floxuridin, fluorodeoxyuridine, fluoruridine deoxyribose, FUdR, proteomic profiling, matrix-assisted laser desorption/ionization time of flight mass spectrometry, MALDI-TOF Mass Spectrometry, liquid chromatography, LC, yttrium Y 90 anti-CEA monoclonal antibody cT84.66, laboratory biomarker analysis, mass spectrometry, pharmacological study, pharmacological studies | City of Hope Medical Center | Liver Metastases, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer | 02/18 | 02/18 | | |
